The University of Chicago Header Logo

Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis.

Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis. Case Rep Oncol Med. 2022; 2022:2767996.

View in: PubMed